Pharming Group Reaffirms 2024 Total Revenue Guidance Of $280M-$295M (14% To 20% Growth)
Portfolio Pulse from Benzinga Newsdesk
Pharming Group reaffirms its 2024 revenue guidance of $280M-$295M, indicating 14% to 20% growth. The company plans to increase revenues through patient conversion to Joenja® therapy, expand leniolisib's market presence, and pursue regulatory approvals globally. They are also exploring acquisitions in rare diseases.
October 24, 2024 | 5:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pharming Group reaffirms its 2024 revenue guidance of $280M-$295M, indicating 14% to 20% growth. The company is focusing on increasing revenues through patient conversion to Joenja® therapy, expanding leniolisib's market presence, and pursuing regulatory approvals globally.
The reaffirmation of revenue guidance suggests confidence in achieving growth targets, which is positive for the stock. The focus on expanding leniolisib's market presence and pursuing regulatory approvals indicates potential for increased future revenues. The mention of potential acquisitions could also drive growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100